BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tamoxifen (Soltamox) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tamoxifen (Soltamox)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04174352-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tamoxifen (Soltamox): Phase 1 readout est. (NCT04174352)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 1\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: FES Imaging to Optimize Tamoxifen for Metastatic Breast Canc
 er\nEstimated primary completion: December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT04174352
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04765098-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT04765098)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2.\nStudy: Tamoxifen Versus Etopos
 ide After First Recurrence in GBM Patients\nEstimated primary completion: 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tamoxi
 fen-soltamox#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04765098
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05780567-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tamoxifen (Soltamox): Phase 3 readout est. (NCT05780567)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 3\, Breast Cancer.\nStudy: Clinica
 l Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Com
 pared With Placebo Combined With Endocrine Therapy in Patients With Breast
  Cancer\nEstimated primary completion: December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05780567
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06195306-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT06195306)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, Breast Cancer.\nStudy: Low Dos
 e Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Red
 uction\nEstimated primary completion: 1 January 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06195306
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04906395-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Tamoxifen (Soltamox): Phase 3 readout est. (NCT04906395)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 3\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: Ovarian Suppression Evaluating Subcutaneous Leuprolide Aceta
 te in Breast Cancer\nEstimated primary completion: 30 January 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04906395
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06364267-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT06364267)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal
  Women at High Risk for Breast Cancer.\nEstimated primary completion: 31 J
 anuary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tamoxife
 n-soltamox#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06364267
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02476786-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT02476786)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, Breast Cancer.\nStudy: Endocri
 ne Treatment Alone for Elderly Patients With Estrogen Receptor Positive Op
 erable Breast Cancer and Low Recurrence Score\nEstimated primary completio
 n: 31 January 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 amoxifen-soltamox#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT02476786
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06914674-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT06914674)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2.\nStudy: Tamoxifen for Advanced 
 Solid Pseudopapillary Tumor of the Pancreas\nEstimated primary completion:
  28 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ta
 moxifen-soltamox#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06914674
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06179303-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT06179303)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: Functional Imaging in Prediction of Response to Abemaciclib 
 for Advanced Hormone Receptor-Positive\, HER2-Negative Breast Cancer\nEsti
 mated primary completion: 1 March 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06179303
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05501704-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT05501704)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: ETHAN - ET for Male BC\nEstimated primary completion: 1 Apri
 l 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/tamoxifen-sol
 tamox#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05501704
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07289035-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT07289035)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2.\nStudy: Early Study on Tamoxife
 n Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modul
 ators.\nEstimated primary completion: 30 June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07289035
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07499999-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT07499999)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: Randomized Double-Blind Phase II Trial of Baby Exemestane Ve
 rsus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cance
 r\nEstimated primary completion: 31 August 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07499999
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03707340-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20271014
DTEND;VALUE=DATE:20271015
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT03707340)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: A Study of Flibanserin in Breast Cancer Survivors on Tamoxif
 en or Aromatase Inhibitors\nEstimated primary completion: 14 October 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/tamoxifen-soltamox#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03707
 340
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979596-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20271104
DTEND;VALUE=DATE:20271105
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT06979596)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2.\nStudy: A Study of MK-5684 in P
 eople With Certain Solid Tumors (MK-5684-015/OMAHA-015)\nEstimated primary
  completion: 4 November 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tamoxifen-soltamox#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06979596
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04740697-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Tamoxifen (Soltamox): Phase na readout est. (NCT04740697)
DESCRIPTION:Tamoxifen (Soltamox)\, phase na\, Breast Cancer.\nStudy: Study 
 to Evaluate the Impact of the Use of Alternative and Complementary Therapi
 es on Therapeutic Adherence in Patients Treated With taMoxifen for Early S
 tage Breast Cancer\nEstimated primary completion: February 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04740697
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06184750-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT06184750)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, Breast Cancer.\nStudy: Finding
  the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal
  Women\, RENAISSANCE Trial\nEstimated primary completion: 31 March 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tamoxifen-soltamox#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0618475
 0
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03011684-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Tamoxifen (Soltamox): Phase 3 readout est. (NCT03011684)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 3.\nStudy: Fertility Preservation 
 Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial\nEstimate
 d primary completion: 31 March 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT03011684
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05891093-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Tamoxifen (Soltamox): Phase 3 readout est. (NCT05891093)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 3\, Breast Cancer.\nStudy: Efficac
 y and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR
 +/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)\nEstimated primary 
 completion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/tamoxifen-soltamox#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05891093
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07806630-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT07806630)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: SHORTened Duration of TAMoxifen\nEstimated primary completio
 n: July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tamoxif
 en-soltamox#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07806630
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06361940-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT06361940)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, Breast Cancer.\nStudy: Molecul
 ar Analyses to Predict Pathways of Endocrine Resistance Following Short Te
 rm Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Posit
 ive HER2-negative Breast Cancer\nEstimated primary completion: September 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tamoxifen-soltam
 ox#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6361940
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06320990-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Tamoxifen (Soltamox): Phase 1 readout est. (NCT06320990)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 1.\nStudy: Chemoprevention With Ta
 moxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing 
 Immediate Resection\nEstimated primary completion: November 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06320990
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06434064-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT06434064)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, Breast Cancer.\nStudy: Tamoxif
 en and Pegylated Liposomal Doxorubicin for the Treatment of Patients With 
 Metastatic or Inoperable\, Locally Advanced Triple Negative Breast Cancer\
 nEstimated primary completion: 30 November 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06434064
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05035836-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20281229
DTEND;VALUE=DATE:20281230
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT05035836)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, Breast Cancer.\nStudy: A Phase
  2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Pati
 ents With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)\nEstima
 ted primary completion: 29 December 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05035836
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492616-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Tamoxifen (Soltamox): Phase 3 readout est. (NCT06492616)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 3\, Breast Cancer.\nStudy: A Study
  of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER
 +\,HER2-\, Early Breast Cancer With High Risk of Recurrence\nEstimated pri
 mary completion: August 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tamoxifen-soltamox#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06492616
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04557449-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20291007
DTEND;VALUE=DATE:20291008
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT04557449)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: Study to Test the Safety and Tolerability of PF-07220060 in 
 Participants With Advance Solid Tumors\nEstimated primary completion: 7 Oc
 tober 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tamoxifen
 -soltamox#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04557449
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05645536-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Tamoxifen (Soltamox): Phase 3 readout est. (NCT05645536)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 3\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: Safety Extension Study for Subjects With HR+\, HER2- Breast 
 Cancer for Subjects Who Have Completed the OVELIA Study\nEstimated primary
  completion: March 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/tamoxifen-soltamox#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05645536
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05161195-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20300628
DTEND;VALUE=DATE:20300629
SUMMARY:Tamoxifen (Soltamox): Phase 4 readout est. (NCT05161195)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 4\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: Roll-over Study to Allow Continued Access to Ribociclib\nEst
 imated primary completion: 28 June 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05161195
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768139-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Tamoxifen (Soltamox): Phase 1/2 readout est. (NCT05768139)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 1/2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: First-in-Human Study of Tersolisib (STX-478) as Monotherap
 y and in Combination With Other Antineoplastic Agents in Participants With
  Advanced Solid Tumors\nEstimated primary completion: July 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05768139
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07535905-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT07535905)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2.\nStudy: Clinical Trial to Obser
 ve the Effects of Tamoxifen on Testosterone Recovery in Medically Castrate
 d Prostate Cancer Patients\nEstimated primary completion: October 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/tamoxifen-soltamox#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07535905
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06942039-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Tamoxifen (Soltamox): Phase 1 readout est. (NCT06942039)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 1.\nStudy: Pilot Study of IT Topot
 ecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years\, Post
  Consolidation\nEstimated primary completion: 31 December 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06942039
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04852887-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20310408
DTEND;VALUE=DATE:20310409
SUMMARY:Tamoxifen (Soltamox): Phase 3 readout est. (NCT04852887)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 3\, Breast Cancer.\nStudy: De-Esca
 lation of Breast Radiation Trial for Hormone Sensitive\, HER-2 Negative\, 
 Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)\n
 Estimated primary completion: 8 April 2031. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04852887
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895511-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20311016
DTEND;VALUE=DATE:20311017
SUMMARY:Tamoxifen (Soltamox): Phase na readout est. (NCT07895511)
DESCRIPTION:Tamoxifen (Soltamox)\, phase na\, Breast Cancer.\nStudy: A Stud
 y of Skipping Radiation Therapy in People With Breast Cancer\nEstimated pr
 imary completion: 16 October 2031. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07895511
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07101159-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT07101159)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, Breast Cancer.\nStudy: Dalpici
 clib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patient
 s\nEstimated primary completion: December 2031. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07101159
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581834-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT07581834)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, Breast Cancer.\nStudy: Efficac
 y and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for E
 arly HR +/HER2- Breast Cancer: a Multicenter\, Prospective Clinical Study\
 nEstimated primary completion: 31 December 2031. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07581834
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06223698-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20320502
DTEND;VALUE=DATE:20320503
SUMMARY:Tamoxifen (Soltamox): Phase 3 readout est. (NCT06223698)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 3\, Breast Cancer.\nStudy: Optimiz
 ing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer\nEs
 timated primary completion: 2 May 2032. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06223698
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06348134-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20340701
DTEND;VALUE=DATE:20340702
SUMMARY:Tamoxifen (Soltamox): Phase 2 readout est. (NCT06348134)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 2\, Breast Cancer.\nStudy: Assessi
 ng the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER
 2+ Breast Cancer Before and After Surgery\nEstimated primary completion: 1
  July 2034. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tamoxifen
 -soltamox#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06348134
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502820-8457@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20360831
DTEND;VALUE=DATE:20360901
SUMMARY:Tamoxifen (Soltamox): Phase 3 readout est. (NCT07502820)
DESCRIPTION:Tamoxifen (Soltamox)\, phase 3\, Breast Cancer.\nStudy: The POW
 ER Trial: Personalised Dose Optimisation With Adjuvant Tamoxifen Therapy i
 n Breast cancER\nEstimated primary completion: August 2036. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07502820
URL:https://assetmemo.bio/drug/tamoxifen-soltamox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
